Intech Biopharm Corporation
TWO: 6461.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shuhui Chen
- Employees
- 90
- Headquarters
- Taipei, Taiwan
- IPO year
- 2014
- Market cap
- NT$2.6B
- Website
- https://www.intechbiopharm.com
Loading 6461…
Loading profile data…Frequently asked questions about 6461
What does Intech Biopharm Corporation (6461.TWO) do?
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its p...
Where does 6461.TWO trade?
Intech Biopharm Corporation (6461.TWO) trades on the Taipei Exchange.
What sector is 6461.TWO in?
Intech Biopharm Corporation (6461.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Intech Biopharm Corporation?
Shuhui Chen is the chief executive officer of Intech Biopharm Corporation (6461.TWO).
Where is Intech Biopharm Corporation headquartered?
Intech Biopharm Corporation is headquartered in Taiwan.
Does 6461.TWO pay a dividend?
Intech Biopharm Corporation (6461.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6461.TWO go public?
Intech Biopharm Corporation (6461.TWO) completed its initial public offering in 2014.